Inverseon comments on LABAs and INV102CR drugs

Inverseon, Inc. (http://www.inverseon.com) comments on Long Acting Beta-Agonists (LABAs) and INV102CR.

“The existing asthma drugs, like all drugs, have limitations. My lab is focused on understanding the mechanisms at work when chronic effects of drugs diverge from their acute effects”

"The existing asthma drugs, like all drugs, have limitations. My lab is focused on understanding the mechanisms at work when chronic effects of drugs diverge from their acute effects," said Richard Bond, PhD, Scientific Founder of Inverseon, Inc. and Prof. of Pharmacology at The University of Houston.

Inverseon has been taking an opposite approach in the chronic treatment of asthma by using ‘inverse agonists’ or blockers, instead of agonists or stimulants, of the beta-receptor. Despite the apparent contradictory approaches, very preliminary data from Inverseon’s work suggests that combining the strategies may be a way to address some of the limitations of long-acting beta-agonists, and possibly steroids when used in combination with INV102CR.